marked.bio

HER2 TKI · small molecule

lapatinib

1 active trials across 6 of our biomarkers, targeting EGFR/HER2. Not approved for any biomarker on marked.bio yet.

Also known as Tykerb, Tyverb.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 1 Phase 1
ALK fusion 0 1 –
BRCA1/2 mutation 0 1 –
EGFR exon 19 deletion / L858R 0 1 –
KRAS G12C 0 1 –
KRAS G12D 0 1 –

Trials

1 of 4 trials shown

  1. Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2013Primary completion 2026-04 NCT01947023

    dabrafenib FDA EUlapatinib

    …o be tested with any Food and Drug Administration (FDA)-approved test (such as Cobas 4800 BRAF V600 Mutation Test)

    BRAF V600EMetastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma